- Home
- ABVC vs NSPR Comparison
ABVC vs NSPR Comparison
Compare ABVC & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- NSPR
- Stock Information
- Founded
- ABVC 2015
- NSPR 2005
- Country
- ABVC United States
- NSPR United States
- Employees
- ABVC N/A
- NSPR N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- ABVC Health Care
- NSPR Health Care
- Exchange
- ABVC Nasdaq
- NSPR Nasdaq
- Market Cap
- ABVC 68.7M
- NSPR 81.8M
- IPO Year
- ABVC N/A
- NSPR N/A
- Fundamental
- Price
- ABVC $2.48
- NSPR $2.04
- Analyst Decision
- ABVC
- NSPR Strong Buy
- Analyst Count
- ABVC 0
- NSPR 2
- Target Price
- ABVC N/A
- NSPR $4.50
- AVG Volume (30 Days)
- ABVC 62.5K
- NSPR 209.0K
- Earning Date
- ABVC 11-03-2025
- NSPR 11-04-2025
- Dividend Yield
- ABVC N/A
- NSPR N/A
- EPS Growth
- ABVC N/A
- NSPR N/A
- EPS
- ABVC N/A
- NSPR N/A
- Revenue
- ABVC $797,916.00
- NSPR $7,779,000.00
- Revenue This Year
- ABVC $735.18
- NSPR $7.48
- Revenue Next Year
- ABVC N/A
- NSPR $104.39
- P/E Ratio
- ABVC N/A
- NSPR N/A
- Revenue Growth
- ABVC 56.52
- NSPR 14.04
- 52 Week Low
- ABVC $0.40
- NSPR $1.59
- 52 Week High
- ABVC $5.48
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- ABVC 37.24
- NSPR 48.17
- Support Level
- ABVC $2.77
- NSPR $1.69
- Resistance Level
- ABVC $3.06
- NSPR $2.10
- Average True Range (ATR)
- ABVC 0.17
- NSPR 0.22
- MACD
- ABVC -0.03
- NSPR 0.02
- Stochastic Oscillator
- ABVC 14.75
- NSPR 65.08
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.